MiNK Therapeutics, Inc. (INKT)
NASDAQ: INKT · Real-Time Price · USD
11.64
+0.41 (3.65%)
At close: Sep 4, 2026, 4:00 PM EDT
11.41
-0.23 (-1.98%)
After-hours: Sep 4, 2026, 7:30 PM EDT
MiNK Therapeutics Stock Forecast
Stock Price Forecast
According to 2 analysts polled by S&P Global, MiNK Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $39. The average 1-year stock price forecast is 235.05% higher than the current stock price, while the lowest is $35 (+200.69%) and the highest is $43 (+269.42%).
Price Target: $39 (+235.05%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for MiNK Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Feb '26 | Mar '26 | Apr '26 | May '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 1 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $35 | Buy | Reiterates | $35 | +200.69% | Aug 14, 2026 |
Financial Forecast
Revenue This Year
3.40M
Revenue Next Year
2.00M
from 3.40M
Decreased by -41.18%
EPS This Year
-1.93
from -2.93
EPS Next Year
-2.65
from -1.93
EPS and Forward PE are based on non-GAAP adjusted numbers.